Meet the Team Behind the Wheel
At the helm sits Lynn Stockwell, CEO and executive chair, who also leads the first iteration of the SPAC. Stockwell isn’t new to the pharmaceutical frontier—she founded Bright Green Corp., a cannabis-focused drugmaker where she still serves as CEO.
Alongside her, Glenn Worman reprises his role as CFO, juggling the same position at the first Drugs Made In America SPAC. Worman also brings financial firepower from his role as partner at SeatonHill Partners LP’s New York office.
Market Ripples and Legal Muscle
Every unit sold in the IPO includes one share of common stock plus one-tenth of a share right upon merger completion, giving investors a slice of the future acquisition.
The IPO, at $500 million, isn’t just the year’s biggest—it’s the largest SPAC debut since Gores Holdings IX Inc. raised $525 million in February 2022, according to Renaissance Capital. That statistic underscores how rare such massive listings have become in a tighter post-SPAC-boom market.
On the legal front, Loeb & Loeb LLP guided the SPAC with a team led by Mitchell Nussbaum and G. Alex Weniger-Araujo. Meanwhile, the underwriters leaned on Ellenoff Grossman & Schole LLP, with Douglas Ellenoff, Stuart Neuhauser, and Anthony Ain steering their side of the deal.
